Alliancebernstein L.P. Akero Therapeutics, Inc. Transaction History

Alliancebernstein L.P.

$290 Billion
Q2 2025

A detailed history of Alliancebernstein L.P. transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, Alliancebernstein L.P. holds 1,536,200 shares of AKRO stock, worth $83.3 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares

1,536,200

Previous 1,251,369 22.76%

Holding current value

$83.3 Million

Previous $50.7 Million 61.82%

% of portfolio

0.03%

Previous 0.02%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$34.04 - $56.28 $9.7 Million - $16 Million	284,831 Added 22.76%	1,536,200 $82 Million
Q1 2025 May 15, 2025	SELL	$21.87 - $57.56 $12.9 Million - $33.8 Million	-587,912 Reduced 31.96%	1,251,369 $50.7 Million
Q4 2024 Feb 12, 2025	SELL	$26.75 - $35.28 $4.76 Million - $6.27 Million	-177,807 Reduced 8.82%	1,839,281 $51.2 Million
Q3 2024 Nov 14, 2024	BUY	$21.45 - $29.34 $2.34 Million - $3.2 Million	109,231 Added 5.73%	2,017,088 $57.9 Million
Q2 2024 Aug 14, 2024	BUY	$18.31 - $24.62 $5.25 Million - $7.06 Million	286,595 Added 17.68%	1,907,857 $44.8 Million
Q1 2024 May 14, 2024	BUY	$17.76 - $31.18 $241,020 - $423,143	13,571 Added 0.84%	1,621,262 $41 Million
Q4 2023 Feb 14, 2024	BUY	$11.38 - $50.33 $3.71 Million - $16.4 Million	325,981 Added 25.43%	1,607,691 $37.5 Million
Q3 2023 Nov 14, 2023	BUY	$41.19 - $52.25 $47.8 Million - $60.7 Million	1,161,305 Added 964.5%	1,281,710 $64.8 Million
Q2 2023 Aug 15, 2023	BUY	$36.89 - $56.88 $1.72 Million - $2.65 Million	46,515 Added 62.95%	120,405 $5.62 Million
Q1 2023 May 15, 2023	BUY	$37.27 - $50.24 $1.47 Million - $1.97 Million	39,310 Added 113.68%	73,890 $2.83 Million
Q4 2022 Feb 14, 2023	BUY	$33.44 - $54.8 $336,138 - $550,849	10,052 Added 40.98%	34,580 $1.89 Million
Q3 2022 Nov 15, 2022	BUY	$10.15 - $34.05 $31,749 - $106,508	3,128 Added 14.62%	24,528 $835,000
Q2 2022 Aug 15, 2022	BUY	$8.0 - $15.01 $43,200 - $81,054	5,400 Added 33.75%	21,400 $202,000
Q3 2021 Nov 10, 2021	SELL	$18.65 - $25.46 $54,084 - $73,834	-2,900 Reduced 15.34%	16,000 $358,000
Q2 2021 Jul 30, 2021	BUY	$24.81 - $32.35 $104,202 - $135,870	4,200 Added 28.57%	18,900 $469,000
Q1 2021 May 06, 2021	SELL	$24.04 - $34.19 $55,292 - $78,637	-2,300 Reduced 13.53%	14,700 $426,000
Q4 2020 Feb 08, 2021	SELL	$25.12 - $29.89 $42,704 - $50,813	-1,700 Reduced 9.09%	17,000 $439,000
Q3 2020 Nov 12, 2020	SELL	$30.79 - $39.92 $104,686 - $135,728	-3,400 Reduced 15.38%	18,700 $576,000
Q2 2020 Aug 13, 2020	BUY	$19.25 - $26.76 $152,075 - $211,404	7,900 Added 55.63%	22,100 $551,000
Q1 2020 May 14, 2020	BUY	$12.8 - $27.05 $181,760 - $384,110	14,200 New	14,200 $301,000

Others Institutions Holding AKRO

# of Institutions

299

Shares Held

92.3M

Call Options Held

1.72M

Put Options Held

901K

View Full List

About Akero Therapeutics, Inc.

Ticker AKRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,417,600
Market Cap $2.52B
Description
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...

More about AKRO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Alliancebernstein L.P., based on Form 13F filings with the SEC.

News

Stay updated on Alliancebernstein L.P. with notifications on news.

Account

Alliancebernstein L.P. Akero Therapeutics, Inc. Transaction History